comparemela.com

Latest Breaking News On - Renal trialist consortium - Page 1 : comparemela.com

SMART-C Meta-Analysis: SGLT2 Inhibitors Reduce Cardiovascular Events

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

George institute for global healthRenal trialist consortiumBrendon neuenResearch fellowGeorge instituteAnalysis cardio renal trialist consortiumHazard ratioConfidence intervalGlucose co transporterMajor adverse cardiovascular outcomesRedefining cardiometabolic

Diabetes Drug Enhances Heart, Kidney Health Outcomes

Diabetes Drug Enhances Heart, Kidney Health Outcomes
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Hiddo heerspinkRenal trialist consortiumSenior researchGeorge institute for global healthAmerican collegeCardiology annual scientific sessionBrendon neuenSenior research fellowGeorge instituteGlobal healthAnalysis cardio renal trialist consortiumProf hiddo heerspinkGlucose co transporterMajor adverse cardiovascular outcomes

EMPA-KIDNEY: Empagliflozin a Win for Patients With CKD

For patients with kidney disease, “the point is: get them on the gliflozin that they can be on,” Janani Rangaswami says.

United statesUnited kingdomBoehringer ingelheim eli lillyDavid preissPatrick markJanani rangaswamiNaveed sattarAmerican heart associationDrug administrationRenal trialist consortiumUniversity of glasgowMd george washington universityPhd university of oxfordAmerican society of nephrology kidney weekEli lillyGeorge washington university

vimarsana © 2020. All Rights Reserved.